.
.
How’s this for a double-whammy: as I’ve covered previously, Ozempic lovingly supplies its beneficiary with turbo-cancer.
But then, we now have evidence to show, ever generous with its side effects, it nullifies the effectiveness of conventional cancer treatments — by a huge margin.
Huge — like the fatasses’ exploding waistlines as soon as they stop taking their drugs.
28% of the test subjects taking GLP-1 agonists like Ozempic responded favorably to their cancer treatments, as opposed to the more than double, 63%, of subjects not taking them who responded positively to theirs.
Via Daily Mail (emphasis added):
“Game-changing weight loss jabs relied on by millions of slimmers and diabetics could cause breast cancer treatments to stop working, experts have warned.
The drugs, which include Ozempic and Wegovy, have ushered in a new era in the battle against obesity, helping dieters shed up to a fifth of their bodyweight.
But, American doctors tracking women being treated for an aggressive form of breast cancer have discovered the injections 'detrimentally affect' how the body responds to chemotherapy and immunotherapy.
It meant that patients on the jabs — collectively known as glucagon-like peptide-1 receptor agonists, or GLP-1s — were less likely to be totally clear of cancer after treatment and more at risk of tumours returning.
British consultant clinical oncologist Dr John Glees said the findings were 'unsettling' and added: 'These weight loss drugs are relatively new, so it's very concerning that patients taking them were less likely to be cancer free after treatment.'
In the study, hundreds of women with early-stage triple negative breast cancer were followed throughout and after treatment.
A few dozen were already taking GLP-1s and continued to do so while having cancer treatment.
Tests two years later showed just 28 per cent of women on GLP-1s responded fully to the cancer therapies, and were clear of cancer…
More than twice as many — 63 per cent — of those not on GLP-1s were cancer free.”
Study: Ozempic also spurs rare form of vision loss
“Non-arteritic anterior ischemic optic neuropathy”: another loving and liberal gift from Eli Lily to the obese peasants in their care.
Via Yahoo! Finance (emphasis added):
“Novo Nordisk's GLP weight-loss drug Ozempic has reportedly been linked to a rare form of vision loss, known as non-arteritic anterior ischemic optic neuropathy (NAION). The study, which has yet to be peer-reviewed, was published on medRxiv and supports findings reported in a Harvard University study from this past July.”
Fucked six ways from Sunday!
